Cavitation Technologies, Inc. FY 2026: Revenue $3K, Net income ($1.4M), EPS $0— 10-K Summary
Cavitation Technologies reported FY 2026 revenue of $3K, down 98.5% YoY, and a net loss of $1.4M, widened from $113K. The decline was due to a shift from product sales to rental and demo income. The company assigned vegetable oil refining patents to Desmet, retaining exclusive licenses for other markets. Cash constraints led to reduced R&D and reliance on partners for commercialization.
How this was made
The 30-second read
Why it matters
The filing reveals a near‑total revenue collapse and a widening net loss, indicating severe short‑term financial stress.
Market read
The news is primarily relevant to traders holding or considering CVAT; broader market impact is negligible.
What to watch
Potential upside from the Permian Basin water‑treatment market and the Alchemy Beverages JV, which are not reflected in the current numbers.
Background
Cavitation Technologies, a niche player in plasma‑based water and oil‑field treatment, released its FY 2026 results via a 10‑K filing.
Ticker impact
Cavitation Technologies filed its FY 2026 10‑K showing revenue of $3K, a 98.5% drop and a net loss of $1.4M.
likely downward pressure as investors price in the sharp revenue collapse and loss expansion.
First‑report 10‑K numbers for a micro‑cap; the scale is small but the negative surprise is material for the stock.
Market effects
Minimal impact on the broader water‑treatment or plasma‑tech sector; the company's decline is company‑specific.
Limited to niche markets where the firm operates; no broader regional effect.
Low global relevance given the company's micro‑cap size and niche focus.
Counterpoint
If the new royalty‑free license and joint ventures materialize, the company could rebound despite the current loss.
Key entities
- companyCavitation Technologies, Inc.
Issuer of the FY 2026 10‑K showing steep revenue decline.
- partnerDesmet
Assigned to manufacture the Nano Reactor® under a royalty‑free license.
